tbuckley/cabot-search huggingface dataset:
Preoperative Drainage in Pancreatic Cancer
Authors: Jonathan Schofield, Andrew M Johnston, Winston F de Mello
Journal: New England Journal of Medicine (2010)

To the Editor: It seems curious that a sizable proportion of troops injured on the battlefield never received morphine or apparently any form of opioid analgesia.The article fails to offer an explanation for this finding.An analysis of the predictors for receiving morphine would be instructive with regard to the relationship between morphine administration and development of PTSD.In addition to the proportion not receiving opioid analgesia, the relatively low morphine dosages provided raise the question of whether injured troops are getting adequate analgesia.
F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy.
Authors: Wei-Jen Shih, Nasrin Ghesani, Zhuang Hongming, Abass Alavi, Steven Schusper, Davis Mozley
Journal: Clinical Nuclear Medicine (2002)

WEI-JEN, SHIH M.D.*,†; NASRIN, GHESANI M.D.‡; ZHUANG, HONGMING M.D.‡; ABASS, ALAVI M.D.‡; STEVEN, SCHUSPER M.D.‡; DAVIS, MOZLEY M.D.‡ Author Information
A Prospective Comparative Study of Parathyroid Dual-Phase Scintigraphy, Dual-Isotope Subtraction Scintigraphy, 4D-CT, and Ultrasonography in Primary Hyperparathyroidism
Authors: Martin Krakauer, Bente Wieslander, Peter S. Myschetzky, Anke Lundstrøm, Theis Bacher, Christian H. Sørensen, Waldemar Trolle, Birte Nygaard, Finn N. Bennedbæk
Journal: Clinical Nuclear Medicine (2015)

Preoperative localization of the diseased parathyroid gland(s) in primary hyperparathyroidism allows for minimally invasive surgery. This study was designed to establish the optimal first-line preoperative imaging modality.Ninety-one patients were studied consecutively in a prospective head-to-head comparison of dual isotope (Tc-MIBI vs I) subtraction parathyroid scintigraphy (PS), dual-phase PS, 4-dimensional (4D) CT, and ultrasonography (US). Surgery, histological confirmation, and postoperative normalization of Ca and parathyroid hormone were the reference standard.Ninety-seven hyperfunctioning parathyroid glands (HPGs) were identified by the reference standard. Sensitivity and specificity for subtraction PS, dual-phase PS, 4D-CT, and US were 93%, 65%, 58%, and 57% as well as 99%, 99.6%, 86%, and 95%, respectively. Interrater agreement was excellent for subtraction PS (κ = 0.96) while only fair for 4D-CT (κ = 0.34). Pinhole imaging and subtraction of delayed images (the latter especially in case of a nodular thyroid gland) increased the sensitivity of subtraction PS. SPECT/low-dose CT did not increase sensitivity but aided in the exact localization of the HPGs. Of 7 negative subtraction PS studies, 4D-CT and US were able to locate 3 and 1 additional HPGs, respectively.Dual isotope pinhole subtraction PS has higher diagnostic accuracy compared with dual-phase PS, 4D-CT, and US as a first-line imaging study in primary hyperparathyroidism. In case of a negative scintigraphy or suspicion of multiglandular disease, 4D-CT and/or US is recommended as a second-line modality. However, diagnostic algorithms should be adapted in accordance with local availability and expertise.
Interaction of Target Oxygen Saturation, Bronchopulmonary Dysplasia, and Pulmonary Hypertension in Small for Gestational Age Preterm Neonates—Reply
Authors: Michele C. Walsh, Juliann M. Di Fiore, Richard J. Martin
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
[<sup>177</sup>Lu-DOTA]<sup>0</sup>-D-Phe<sup>1</sup>-Tyr<sup>3</sup>-Octreotide (<sup>177</sup>Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
Authors: Richard P. Baum, Andreas W. Kluge, Harshad Kulkarni, Ulrike Schorr-Neufing, Karin Niepsch, Norman Bitterlich, Cees J.A. van Echteld
Journal: Theranostics (2016)

Purpose: To characterise efficacy and safety of 177 Lu-DOTATOC as agent for peptide receptor radiotherapy (PRRT) of advanced neuroendocrine tumours (NET).Patients and methods: Fifty-six subjects with metastasized and progressive NET (50% gastroenteral, 26.8% pancreatic, 23.2% other primary sites) treated consecutively with 177 Lu-DOTATOC were analysed retrospectively.Subjects were administered 177 Lu-DOTATOC (mean 2.1 cycles; range 1-4) as 7.0GBq (median) doses at three-monthly intervals.Efficacy was analysed using CT and/or MRI according to RECIST 1.1 criteria and results were stratified for the number of administered cycles and the primary tumour origin.Results: In the total NET population (A), median progression-free (PFS) and overall survival (OS) were 17.4 and 34.2 months, respectively, assessed in a follow-up time (mean ± SD) of 16.1 ± 12.4 months.In patients receiving more than one cycle, mean follow-up time was 22.4 ± 11.0 months for all NETs (B) and PFS was 32.0 months for all NETs (B), 34.5 months for GEP-NET (C), and 11.9 months for other NETs (D).Objective response rates (Complete/Partial Responses) were 33.9%, 40.6%, 54.2%, and 0% for A, B, C, and D groups, respectively, while disease control rates in the same were 66.1%, 93.8%, 100%, and 75%.Complete responses (16.1%, 18.8% and 25.0% for groups A, B and C) were high, 78% of which were maintained throughout the follow up.There were no serious adverse events.One case of self-limiting grade 3 myelotoxicity was reported.Although 20% of patients had mild renal insufficiency at baseline, there was no evidence of exacerbated or de novo renal toxicity after treatment.Conclusion: 177 Lu-DOTATOC is a novel agent for PRRT with major potential to induce objective tumour responses and sustained disease control in progressive neuroendocrine tumours, even when administered in moderate activities.The observed safety profile suggests a particularly favourable therapeutic index, including in patients with impaired bone marrow or renal function, which reflects a uniquely low uptake of 177 Lu-DOTATOC by normal organs.
SAT0412 Disease Activity in Patients with Primary SjÖgren's Syndrome Followed by Spanish Rheumatology Departments
Authors: M. Fernandez Castro, J.L. Andreu, A. Olivé, J. Rosas, V. Martínez Taboada, C. Sánchez-Piedra, L. Romaní, S. Melchor, B. Moreira, E. Raya, M. Rodriguez Lόpez, N. Cid, E. Júdez, C. Moriano, V. Torrente, H. Corominas, B. García Magallόn
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Primary Sjögren syndrome (pSS) is a systemic autoimmune disease affecting primarily the exocrine glandular system. More than half of the patients with 10 or more years of follow up show extra-glandular manifestations, which will be determinant for the prognosis. Several validated methods are available in order to assess activity in pSS, including the Sjogren9s Syndrome Disease Activity Index (SSDAI) and the EULAR Sjogren9s Syndrome Disease Activity Index ESSDAI). <h3>Objectives</h3> The aim of our study was to evaluate disease activity in a representative cohort of patients followed in rheumatology departments. <h3>Methods</h3> We conducted a multicenter descriptive transversal study of a cohort of Spanish pSS patients fulfilling European/American criteria. It is a randomised register of patients obtained from 33 spanish rheumatology departments. We used SSDAI and ESSDAI in every patient. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates, with their deviations and interquartile ranges (p25-p75). <h3>Results</h3> A total of 437 patients were included. Median score for SSDAI was 1 (0-3, p25-p75) and for ESSDAI was 2 (0-4, p25-p75). More than 95% of patients did not show fever, night sweating or weight loss. Twenty percent of them manifested weakness. Less than 5% of patients suffered glandular inflammatory disease or lymphadenopathy. Thirty two percent referred joint pain with stiffness but only 3% had true sinovitis. Fourteen patients (3%) showed cutaneous involvement. Fourteen percent of patients developed pleural involvement. High resolution CT was performed in 89 patients and showed interstitial disease in less than 4% percent of them. Serum creatinine was elevated in 3% of the cases. Seven patients developed tubular acidosis and 2 patients glomerular involvement. Less than two percent of patients had central nervous system involvement and 3% had peripheral nervous system involvement. Twenty seven percent of patients developed some kind of cytopenia: anaemia 14%, lymphopenia 14%, neutropenia 7% and thrombocytopenia, 9%. Twenty three percent had monoclonal component and/or hypoclomplementemia and/or hypergammaglobulinemia and/or high Ig G levels. Four percent showed cryoglobulinemia and/or hypergammaglobulinemia and/or high Ig G levels and/or recent hypogammaglobulinemia or a recent IgG levels fall. <h3>Conclusions</h3> pSS patients show low scores at the systemic damage indexes. Most affected domains were haematological, biological and articular. Considering parenchymatous and pleural involvement, lung is the organ most frequently involved. <h3>Disclosure of Interest</h3> None declared
The Fetal Alcohol Syndrome
Authors: Sterling K. Clarren, David W. Smith
Journal: New England Journal of Medicine (1978)

Behold, thou shalt conceive, and bear a son; and now drink no wine or strong drink....(Judges 13:7)THE potential teratogenic effects of alcohol have been suspected for centuries, but it was not until the work of Lemoine in 19681 and the independent observations of Jones and Smith in 19732 that a distinct, dysmorphic condition associated with maternal, gestational alcoholism was described in medical literature.Since alcoholics frequently abuse other drugs, notably caffeine, nicotine and diazepam, and generally have unbalanced diets, it was initially questioned if ethanol could be isolated as the etiologic agent responsible for the "fetal alcohol syndrome." . . .
The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer
Authors: Bruce Brockstein, Mario Lacouture, Mark Agulnik
Journal: Journal of the National Comprehensive Cancer Network (2008)

Epidermal growth factor receptor (EGFR) is overexpressed in most head and neck cancers and correlates with poor prognosis. In the past few years, numerous clinical trials for head and neck cancer have tested monoclonal antibodies against EGFRs and small molecule inhibitors of EGFR tyrosine kinase. Results led to FDA approval of cetuximab with concomitant radiotherapy for treating locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), and as a single agent in patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy failed. This article reviews the biology of EGFR as it pertains to head and neck cancer, including the important clinical trials of EGFR monoclonal antibodies and tyrosine kinase inhibitors in SCCHN, alone and with concomitant radiotherapy. Molecular and clinical markers of response and outcome are also discussed.
Physical Medicine and Rehabilitation
Authors: Charles D. Bonner
Journal: New England Journal of Medicine (1964)

Vocational Counseling, Training and Job PlacementImmediately after World War I there was a flurry of interest in increasing job opportunities for the disabled. As in many phases of rehabilitation, this interest died down in many areas in the years between the two wars. However, legislation such as the Federal Vocational Rehabilitation Act of 1920 resulted from this interest.7 Subsequent legislation recognized the importance of close co-operation with workmen's compensation agencies of the states. The Barden-LaFollette Act of 1943 broadened the program to include medical services, and the current Vocational Rehabilitation Act of 1954 (Public Law 565) stated these needs . . .
Importance of standardisation of HAI definitions in interpretation of international and/or multinational prevalence studies
Authors: M Cotter, S Donlon, F Fitzpatrick
Journal: Eurosurveillance (2012)

Preview this article: Importance of standardisation of HAI definitions in interpretation of international and/or multinational prevalence studies, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/37/art20269-en-1.gif
Mode of Inheritance of Resistance to Rous Sarcoma Virus in Chickens
Authors: Waters, Nelson F., Burmester, B. R.
Journal: JNCI Journal of the National Cancer Institute (1961)

Journal Article Mode of Inheritance of Resistance to Rous Sarcoma Virus in Chickens Get access Nelson F. Waters, Nelson F. Waters Regiona Poultry Research Laboratory,2East Lansing, Michigan Search for other works by this author on: Oxford Academic PubMed Google Scholar B. R. Burmester B. R. Burmester Regiona Poultry Research Laboratory,2East Lansing, Michigan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 27, Issue 3, September 1961, Pages 655–661, https://doi.org/10.1093/jnci/27.3.655 Published: 01 September 1961 Article history Received: 17 April 1961 Published: 01 September 1961
AB0657 The Evaluation of Diagnostic Accuracy Between EULAR/ACR Provisional Classification for PMR and 4 Other Criterion: Table 1
Authors: M. Yokoe, Y. Noguchi
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Polymyalgia rheumatica (PMR) is a common rheumatic disorder in the elderly. However, No gold standard for the diagnosis of PMR exists. In 2012, EULAR/ACR classification criteria for PMR had been presented. This time, we compared the diagnostic accuracy between EULAR/ACR classification (scoring algorithm without Ultrasound -3 required criteria) and Bird criteria, Chuang criteria, Kyle criteria, and Nobunaga criteria for PMR. <h3>Objectives</h3> To investigate the diagnostic accuracy including sensitivity and specificity of each criteria and coefficient of agreement. In addition Receiver-Operating Characteristic (ROC) analysis was performed. <h3>Methods</h3> We evaluated restrospectively 80 cases that had been suspecious for PMR with the 3 positive factors or more of the Bird criteria from June 2008 to August 2014. Final diagnosis of PMR was confirmed during 26 weeks of observation. <h3>Results</h3> Of 80 patients, 53 (66.3%) were female; average age was 74.1±8.7 years old (48-87). Following the EULAR/ACR study design, we decided the final diagnosis of PMR after 26 weeks of starting steroid treatment. Finally, PMR cases numbered 62 and non-PMR cases were 18 cases (Prevalence: 77.5%). All 80 cases were matched for the Bird criteria (sensitivity 100%, specificity 0%). 5 cases did not have creatinine kiinase measured at the initial diagnosis, Nobunaga criteria was adapted in only 75 cases. <h3>Conclusions</h3> EULAR/ACR classification with statistical significance performed better than the other PMR criterion. This study did not include many control cases. High prevalence prevented a high κ(kappa) value with EULAR/ACR classification. From the ROC analysis, the EULAR/ACR classification had a high AUC value of 0.7133. Presently, the EULAR/ACR classification is the most reliable criteria for PMR. <h3>References</h3> Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484-92. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979 Oct;38(5):434-9. <h3>Disclosure of Interest</h3> None declared
Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR4.5) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update
Authors: Michael Mauro, Jerald Radich, Jorge E. Cortes, Shaker Dakhil, Christopher Keir, Sandy Yi, Martha Wadleigh, Vivian G. Oehler, Thomas Ervin, Stuart Goldberg, Michael Savona
Journal: Blood (2013)
Methicillin resistant Staphylococcus aureus in German hospitals develop narrower patterns of antimicrobial resistance
Authors: W Witte, C Braulke, D Heuck, C Cuny
Journal: Eurosurveillance (2000)

The prevalence of methicillin resistant Staphylococcus aureus (MRSA) in German hospitals has continued to increase, but the range of anti-microbials to which they are resistant has decreased. The trend cannot be attributed to changes in antibiotic consump
AB0905 Osteocalcin Levels Can Predict Significant Increases in Bone Mineral Density After Teriparatide Treatment
Authors: R. Fonseca, D. Gonçalves, R. Vieira, J. Abelha-Aleixo, G. Terroso, M. Bernardes, L. Costa
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Biochemical markers of bone turnover levels have been suggested as predictors of long-term response in bone mass density (BMD) to teriparatide. However, its usefulness in clinical practice is unknown. <h3>Objectives</h3> To identify the patients that will have significant increases in BMD after teriparatide using osteocalcin (OC) levels. <h3>Methods</h3> Prospective observational study was performed. OC was measured at baseline, 3 months (M) and 18 M and BMD at baseline and 18 M (LUNAR Expert 1320R). Correlation between OC levels and BMD changes was evaluated by Spearman rank correlation analysis. Discriminant cut-off values for OC (baseline and 3M changes) in predicting "threshold" BMD increases &gt;15% were determined using receiver operating characteristics curve (ROC). Kappa coefficient was calculated to identify the agreement between patients identified as good responders by their OC levels. <h3>Results</h3> 57 patients (91.2% female) with mean age of 67.65±8.8 years were included. After treatment, median BMD change in lumbar spine (LS) was 0.088 g/cm<sup>2</sup> (10.65%). Median baseline OC level was 18.9 ng/mL [4.2 – 71.3] and median 3M OC change was 27.5 ng/mL [0.30 – 93.50]. LS BMD gains after treatment correlated significantly with baseline OC (r=0.324; p=0.036) as well with 3M OC changes (r=0.336; p=0.049). Baseline OC and 3M OC changes showed a good accuracy in predicting &gt;15% LS BMD change (area under the curve AUC 0.694, p=0.03 and AUC 0.748, p=0.017, respectively). Baseline OC of 26.75 ng/mL predict 15% improvement in BMD with sensitivity (S) 40%, specificity (E) 92.6%, positive predictive value (PPV) 74.84%, negative predictive value (NPV) 74%, positive likelihood ratio (LR) 5.4 and negative LR 0.65. 39.3 ng/mL in 3M OC changes predict 15% improvement in BMD with: S 50%, E 91.3%, PPV 74.89%, NPV 41.67%, positive LR 5.74 and negative LR 0.55. We found a good agreement (Kappa 0.697; p=0.01) between patients identified as good responders (baseline OC ≥26.75 ng/mL and 3M OC changes≥39.3 ng/mL). <h3>Conclusions</h3> 26.75 ng/mL in baseline OC and 39.3 ng/mL increases in OC were the most convenient predictors of BMD response in clinical practice. These values can be used either to select patients (that will probably have good results) as well for assessing adherence and treatment response at 3 months. <h3>Disclosure of Interest</h3> None declared
Lumbar Puncture
Authors: W. Gooddy
Journal: BMJ (1953)

<h3>Abstract</h3> The Peer Assisted Learning program at Sacramento State University (PAL) was established in 2012 with one section supporting introductory chemistry. It now serves 17 gatekeeper courses in Biology, Chemistry, Mathematics, Physics, and Statistics, enrolling approximately 1,400 students annually. Adapting the Peer-Led Team Learning model, PAL Facilitators do not teach, tutor, or even confirm answers; they do ask scaffolding questions, provide encouragement, and ensure that all group members participate in problem-solving. Here we assess the efficacy of the program in terms of student success in the parent course. As PAL is an opt-in program, we employ propensity score matching techniques to account for confounding factors. Our analysis of 11 classes shows that PAL provides an average course GPA bump ranging from .23 to .71 grade points (mean .42). Compared to the non-PAL baseline course GPA, this amounts to an increase of 9% to 51% (mean 23%). We consider data from over 25,000 students, and our propensity score analysis uses over 10,000 students (4,519 PAL, 5,814 non-PAL) for whom appropriate matches could be found.
Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011
Authors: Cecilie Blimark, Erik Holmberg, Gunnar Juliusson, Hareth Nahi, Forsberg Karin, Ingemar Turesson, Lucia Ahlberg, Ronald Svensson, Olle Linder, Kristina Carlsson, Sigurdur Y Kristinsson
Journal: Blood (2013)